Stock Track | Laekna Soars as Obesity Drug Shows Promise in Clinical Trials

Stock Track10-20

Shares of Laekna Biotechnology Holdings Ltd. (HKG:02105) surged over 17% on Thursday after the company announced a key milestone in the clinical development of LAE102, its investigational treatment for overweight and obesity.

LAE102 is a novel antibody that targets the ActRIIA protein, which plays a crucial role in muscle repair and fat processing in the body. By inhibiting ActRIIA, the drug aims to promote lean muscle growth while reducing fat mass, potentially offering a new therapeutic approach for obesity.

In a filing with the Hong Kong bourse, Laekna revealed that it has started dosing patients in a subcutaneous cohort as part of the ongoing Phase 1 clinical trial for LAE102. As of September 30th, 50% of the planned groups for intravenous injection had already received their doses, marking significant progress in the study. With obesity rates on the rise globally, a safe and effective treatment like LAE102 could have substantial market potential if it successfully navigates the clinical and regulatory process.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132806078?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-20 11:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132806078","market":"us","top_or_hot":-1,"title":"Stock Track | Laekna Soars as Obesity Drug Shows Promise in Clinical Trials","media":"Stock Track","content":"<p>Shares of Laekna Biotechnology Holdings Ltd. (HKG:02105) surged over 17% on Thursday after the company announced a key milestone in the clinical development of LAE102, its investigational treatment for overweight and obesity.</p>\n\n<p>LAE102 is a novel antibody that targets the ActRIIA protein, which plays a crucial role in muscle repair and fat processing in the body. By inhibiting ActRIIA, the drug aims to promote lean muscle growth while reducing fat mass, potentially offering a new therapeutic approach for obesity.</p>\n\n<p>In a filing with the Hong Kong bourse, Laekna revealed that it has started dosing patients in a subcutaneous cohort as part of the ongoing Phase 1 clinical trial for LAE102. As of September 30th, 50% of the planned groups for intravenous injection had already received their doses, marking significant progress in the study. With obesity rates on the rise globally, a safe and effective treatment like LAE102 could have substantial market potential if it successfully navigates the clinical and regulatory process.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Laekna Soars as Obesity Drug Shows Promise in Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Laekna Soars as Obesity Drug Shows Promise in Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-20 11:08 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Laekna Biotechnology Holdings Ltd. (HKG:02105) surged over 17% on Thursday after the company announced a key milestone in the clinical development of LAE102, its investigational treatment ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02105","symbol_name":"来凯医药-B","start_time":0,"source_url":"","article_id":"1132806078","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132806078","pubTimestamp":1729393713,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Laekna Biotechnology Holdings Ltd.  surged over 17% on Thursday after the company announced a key milestone in the clinical development of LAE102, its investigational treatment for overweight and obesity.LAE102 is a novel antibody that targets the ActRIIA protein, which plays a crucial role in muscle repair and fat processing in the body. By inhibiting ActRIIA, the drug aims to promote lean muscle growth while reducing fat mass, potentially offering a new therapeutic approach for obesi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02105":"来凯医药-B"},"translate_title":"随着肥胖药物在临床试验中显示出前景，Laekna股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1},"content_text":"Shares of Laekna Biotechnology Holdings Ltd. (HKG:02105) surged over 17% on Thursday after the company announced a key milestone in the clinical development of LAE102, its investigational treatment for overweight and obesity.\nLAE102 is a novel antibody that targets the ActRIIA protein, which plays a crucial role in muscle repair and fat processing in the body. By inhibiting ActRIIA, the drug aims to promote lean muscle growth while reducing fat mass, potentially offering a new therapeutic approach for obesity.\nIn a filing with the Hong Kong bourse, Laekna revealed that it has started dosing patients in a subcutaneous cohort as part of the ongoing Phase 1 clinical trial for LAE102. As of September 30th, 50% of the planned groups for intravenous injection had already received their doses, marking significant progress in the study. With obesity rates on the rise globally, a safe and effective treatment like LAE102 could have substantial market potential if it successfully navigates the clinical and regulatory process.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132806078"}